Post-Market Feasibility Study of the Tenon Medical CATAMARAN™ SI Joint Fusion System

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-14

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the outcomes of patients with sacroiliac joint pain treated with the CATAMARAN SI Joint Fusion System.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tenon Medical CATAMARAN™ SI Joint Fusion System CT Scan Study

NCT05628142

Sacroiliac Joint Disruption Degenerative Sacroiliitis

UNKNOWN NA

CT Follow-Up of the SImmetry Sacroiliac Joint Fusion System

NCT02425631

Sacroiliitis

COMPLETED

First-in-Human Safety Study for Fractomer™ Biomatrix

NCT07151638

Soft Tissue Soft Tissue Defects Subcutaneous Injection

COMPLETED NA

Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter

NCT02349308

Pain; Dialysis Catheter

COMPLETED

Novel Guidance Device for Image Fusion and Needle Guidance in Lung, Liver or Kidney Biopsy

NCT04039529

Liver Biopsy Lung Biopsy Kidney Biopsy

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a multi-center post-market study to evaluate the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with the CATAMARAN SI Joint Fusion System.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sacroiliac Joint Disruption Degenerative Sacroiliitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CATAMARAN SI Joint Fusion System

Placement of the Catamaran Fixation Device

Group Type EXPERIMENTAL

CATAMARAN SI Joint Fusion System

Intervention Type DEVICE

Placement of the Catamaran Fixation Device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CATAMARAN SI Joint Fusion System

Placement of the Catamaran Fixation Device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of sacroiliac joint disruption or degenerative sacroiliitis based on ALL of the following:

* Patient has pain at or close to the posterior superior iliac spine (PSIS) with possible radiation into buttocks, posterior thigh or groin and can point with a single finger to the location of pain (Fortin Finger Test), and
* Patient has at least 3 of 5 physical examination maneuvers specific for SI joint pain (Fabers, Compression, Distraction,Thigh thrust, Gaenslen's test, and/or Sacral thrust test), and
* Patient has improvement in lower back pain VAS of at least 50% of the pre injection VAS after fluoroscopic controlled injection of local anesthetic into affected SI joint(s) (including previous documented test \<6 months ago)
* Patient has failed conservative care (non-surgical) \> 6 months
* Patient has a pre-operative Oswestry Disability Index score \> 30%
* Patient has a pre-operative SI joint pain score of \> 50 on a 0-100 mm visual analog scale (VAS)
* Patient, or authorized representative, signs a written Informed Consent form to participate in the study
* Patient is willing and able to complete study follow-up requirements

Exclusion Criteria

* Planned bi-lateral SI joint fixation
* Severe lower back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, and lumbar vertebral body fracture (this is done by physical exam, medical history, and MRI/CT/X-ray as required)
* Other known sacroiliac pathology such as: sacral dysplasia, inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA- associated spondyloarthropathy), tumor, acute fracture, crystal arthropathy
* History of recent (\<1 year) fracture of the pelvis with documented malunion, non-union of sacrum or ilium or any type of internal fixation of the pelvic ring
* Severe osteoporosis
* Paget's disease, osteomalacia, osteomalacia or other metabolic bone disease
* Any condition or anatomy that makes treatment with the CATAMARAN SI Joint Fusion System infeasible including deformity
* Known allergy to titanium or titanium alloys
* Morbid obesity
* Active malignancy: a history of any invasive malignancy (except non-melanoma skin cancer), unless the subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least five years
* Patient has systemic infection or active infection at the treatment site
* Chronic rheumatologic condition (e.g., rheumatoid arthritis)
* Patient has uncontrolled diabetes
* Patient is currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation
* Prominent neurologic condition that would interfere with physical therapy
* Patient is pregnant or wishes to become pregnant in the next two years
* Patient is not likely to comply with the follow-up evaluation schedule
* Patient is participating in a clinical trial of another investigational drug or device in which the primary endpoint has not occurred
* Patient has a psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation
* Known or suspected drug or alcohol abuse
* Patient is a prisoner or a ward of the state

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No